We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

MRI Can Halve Prostate Cancer Over-Diagnosis

By MedImaging International staff writers
Posted on 29 Jul 2021
Print article
Image: MRI screening can significantly reduce prostate cancer over-diagnoses (Photo courtesy of Getty Images)
Image: MRI screening can significantly reduce prostate cancer over-diagnoses (Photo courtesy of Getty Images)
A new study suggests that screening by magnetic resonance imaging (MRI) and targeted biopsies could significantly reduce prostate cancer (PC) over-diagnosis.

Researchers at Karolinska Institutet (Solna, Sweden) and Karolinska University Hospital (Stockholm, Sweden) conducted a population-based study of 12,750 (50 to 74 years of age). Those with prostate-specific antigen (PSA) levels of 3 ng/ml or higher were randomly assigned to undergo standard biopsy or MRI, with targeted biopsy added if MRI results suggested PC. The primary outcome was proportion of men in whom clinically significant PC was diagnosed; a key secondary outcome was the detection of clinically insignificant cancers.

The results showed that 1,532 men had PSA levels of 3 ng/ml or higher; 603 were assigned to the standard biopsy group and 929 to the targeted biopsy group. In intention-to-treat analysis, clinically significant cancer was diagnosed in 21% in the targeted biopsy group, as compared with 18% in the standard biopsy group. The percentage of clinically insignificant cancers was lower in the targeted biopsy group (4%) than in the standard biopsy group (12%). The study was published on July 9, 2021, in The New England Journal of Medicine (NEJM).

“High rates of overdiagnosis are a critical barrier to organized PC screening. Most countries have not introduced nationwide PC screening, as current methods result in over-diagnoses and excessive and unnecessary biopsies,” said lead author urologist Tobias Nordström, PhD, of Karolinska Institutet. “Our results show that modern methods for PC screening maintain the benefits of screening, while decreasing the harms substantially. This addresses the greatest barrier to the introduction of nationwide screening.”

Current PC screening methods, which include prostate-specific antigen (PSA) tests combined with traditional biopsies, often result in unnecessary biopsies, and the detection of numerous minor low-risk tumors. Consequently, no country except Lithuania has chosen to introduce a nationwide PC screening programme, as the benefits do not exceed the disadvantages.

Related Links:
Karolinska Institutet
Karolinska University Hospital



Print article
CIRS
Radcal

Channels

Industry News

view channel
Illustration

Fujifilm Introduces AI-Powered Chest X-Ray Software in Collaboration with Lunit

Fujifilm Corporation (Tokyo, Japan) has announced that its software for analyzing chest X-ray developed with the core artificial intelligence (AI) technology of Lunit (Seoul, Korea) will be commercially... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.